Medications that treat opioid use disorder (OUD) — such as methadone, buprenorphine and extended-release naltrexone — are proven to save lives. However, a new study revealed that less than 15% of Americans with OUD receive these medications. Its lead author laid out three actions the U.S. should prioritize to increase access.
